Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP Health Policy Clique Set to Urge Govt to Skip Off-Year Re-Pricing Next Year, but Explore Middle Ground at Same Time
November 27, 2020
-
REGULATORY MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing
November 26, 2020
-
REGULATORY 3 Pharma Groups: Limit Scope of Off-Year Re-Pricing to Drugs with “Significantly Large Discrepancy Rates”
November 26, 2020
-
REGULATORY MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine
November 26, 2020
-
REGULATORY Ryukaikon Confab Held after 17 Month Hiatus, COVID-19 Impact on Drug Distribution Discussed
November 25, 2020
-
ACADEMIA Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL
November 25, 2020
-
BUSINESS Improved Hygiene amid COVID-19 Hit Infectious Disease Meds, Big-Seller Hopefuls See Slow Uptake
November 24, 2020
-
REGULATORY 1st Humira Biosimilar to Join NHI Price List on Nov. 25
November 24, 2020
-
BUSINESS Big 3 Generic Makers Log 7.2% Growth in 1st Half, Suffer Sluggish Japan Sales on Price Cuts, COVID-19: Jiho Tally
November 20, 2020
-
ORGANIZATION EFPIA Japan Chief Frets Declining Priority for Japan Market since 2018 Pricing Overhaul
November 19, 2020
-
ACADEMIA National Cancer Center Exploring Effectiveness of Frontline Use of Multigene Panel Testing for Solid Tumors
November 18, 2020
-
REGULATORY Drug Makers Disclosing as Much Cost Info as Possible in Price Negotiations, JPMA Chief Rebuts Concerns Aired in Project Review
November 17, 2020
-
REGULATORY With Consensus on 13 Topics Delayed by COVID-19, ICH Expected to Restrict Selection of New Topics at Virtual Assembly
November 16, 2020
-
REGULATORY “No Comment with Prejudgment” on COVID-19 Shots for Children: Minister
November 16, 2020
-
BUSINESS Generic Makers Seeking to Invalidate Feburic Patent, Can They Get Full Indications?
November 13, 2020
-
BUSINESS New BMS to Rev Up Open Innovation Drive in Japan, Evolve Portfolio in 6 Focus Areas: Country CEO
November 12, 2020
-
REGULATORY Oral Semaglutide, Gilead JAK Inhibitor, Takeda’s PARP Med OK’ed for Listing on Nov. 18
November 11, 2020
-
BUSINESS Nichi-Iko Recalls 7 More Products, Critical Eyes from Healthcare Professionals
November 11, 2020
-
BUSINESS Incyte Gearing Up for Solo Marketing in Japan, Set to Double Workforce to 70 Staffers
November 10, 2020
-
REGULATORY Japan to Set New Technical Fee for CureApp’s Quit Smoking App
November 10, 2020
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…